For additional information, please visit: https://www.onclive.com/view/fda-grants-breakthrough-status-to-mk-6482-for-select-vhl-disease-associated-rcc Also check out the abstract presented at the 2020 ASCO meeting: https://meetinglibrary.asco.org/record/185945/abstract
Permanent link to this article: https://inheritedcancer.net/post92220/
There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Von-Hippel Lindau (VHL) Disease: Among patients with VHL-associated clear cell renal cell carcinoma (RCC), a recent study suggested potential benefit …
Permanent link to this article: https://inheritedcancer.net/9nls2020/
Additional exciting advances include the results of a new drug (pazopanib) to treat an inherited cancer condition called von Hippel-Lindau Disease (VHL), in which patients are predisposed to kidney cancers, pancreatic tumors, and hemangioblastomas (i.e., tumors involving the blood vessels). Study results showed that among 31 patients with VHL, overall response rate with the drug …
Permanent link to this article: https://inheritedcancer.net/8nlw2019/
